Ocuphire Pharma Alpha and Beta Analysis
| OCUPDelisted Stock | USD 1.13 0.06 5.04% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Ocuphire Pharma. It also helps investors analyze the systematic and unsystematic risks associated with investing in Ocuphire Pharma over a specified time horizon. Remember, high Ocuphire Pharma's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Ocuphire Pharma's market risk premium analysis include:
Beta (1.21) | Alpha (0.62) | Risk 3.67 | Sharpe Ratio (0.05) | Expected Return (0.20) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Ocuphire |
Ocuphire Pharma Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Ocuphire Pharma market risk premium is the additional return an investor will receive from holding Ocuphire Pharma long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Ocuphire Pharma. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Ocuphire Pharma's performance over market.| α | -0.62 | β | -1.21 |
Ocuphire Pharma Fundamentals Vs Peers
Comparing Ocuphire Pharma's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Ocuphire Pharma's direct or indirect competition across all of the common fundamentals between Ocuphire Pharma and the related equities. This way, we can detect undervalued stocks with similar characteristics as Ocuphire Pharma or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Ocuphire Pharma's fundamental indicators could also be used in its relative valuation, which is a method of valuing Ocuphire Pharma by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Ocuphire Pharma to competition |
| Fundamentals | Ocuphire Pharma | Peer Average |
| Return On Equity | -0.36 | -0.31 |
| Return On Asset | -0.21 | -0.14 |
| Profit Margin | (0.86) % | (1.27) % |
| Operating Margin | (7.49) % | (5.51) % |
| Current Valuation | (6.57 M) | 16.62 B |
| Shares Outstanding | 26.2 M | 571.82 M |
| Shares Owned By Insiders | 7.33 % | 10.09 % |
Ocuphire Pharma Opportunities
Ocuphire Pharma Return and Market Media
The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Intellia Therapeutics, Inc. Reports Q2 Loss, Lags Revenue Estimates | 08/08/2024 |
2 | Ocuphire Pharma Announces Financial Results for Second Quarter 2024 and Provides Corporate Update | 08/13/2024 |
3 | Analyst Forecasts For Ocuphire Pharma, Inc. Are Surging Higher | 08/19/2024 |
4 | Ocuphire Pharma Initiates VEGA-3 Phase 3 Trial Evaluating Phentolamine Ophthalmic Solution 0.75 percent for Presbyopia | 09/05/2024 |
5 | Ocuphire Pharma Announces Publication of Full Phase 3 Results of Phentolamine Ophthalmic Solution 0.75for Pharmacologically-Induced Mydriasis in Ophthalmology | 09/30/2024 |
6 | Ophthalmic Biopharmaceutical Ocuphire Pharma Shifts Focus To Gene Therapy Through Opus Genetics Stock Deal | 10/23/2024 |
About Ocuphire Pharma Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Ocuphire or other delisted stocks. Alpha measures the amount that position in Ocuphire Pharma has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
Ocuphire Pharma Upcoming Company Events
As portrayed in its financial statements, the presentation of Ocuphire Pharma's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Ocuphire Pharma's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Ocuphire Pharma's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Ocuphire Pharma. Please utilize our Beneish M Score to check the likelihood of Ocuphire Pharma's management manipulating its earnings.
| 4th of April 2024 Upcoming Quarterly Report | View | |
| 20th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 4th of April 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Ocuphire Pharma
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.
Other Consideration for investing in Ocuphire Stock
If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world |